

# Laura E Targownik

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4486507/laura-e-targownik-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173  
papers

5,713  
citations

41  
h-index

71  
g-index

225  
ext. papers

7,071  
ext. citations

5.2  
avg, IF

5.83  
L-index

#	Paper	IF	Citations
173	Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 2366-73	27.4	302
172	Use of proton pump inhibitors and risk of osteoporosis-related fractures. <i>Cmaj</i> , <b>2008</b> , 179, 319-26	3.5	279
171	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , <b>2016</b> , 150, 734-757.e1	13.3	261
170	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , <b>2015</b> , 148, 1035-1058.e3	13.3	251
169	The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1228-35	0.7	192
168	Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. <i>Gastroenterology</i> , <b>2010</b> , 138, 896-904	13.3	185
167	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1120-1134	0.7	167
166	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1145-54	59.2	158
165	Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. <i>Gastrointestinal Endoscopy</i> , <b>2004</b> , 60, 865-74	5.2	133
164	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology</i> , <b>2019</b> , 156, 1345-1353.e4	13.3	132
163	Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. <i>Gut</i> , <b>2014</b> , 63, 552-8	19.2	124
162	Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 1459-1466	6.9	112
161	Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective?. <i>Hepatology</i> , <b>2003</b> , 37, 366-77	11.2	101
160	A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 974-84	6.1	101
159	The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. <i>Osteoporosis International</i> , <b>2013</b> , 24, 1161-8	5.3	99
158	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1840-1848	0.7	91
157	The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. <i>Gastroenterology</i> , <b>2008</b> , 134, 937-44	13.3	90

156	The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1001-12; quiz 1013	0.7	89
155	The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1361-9	0.7	86
154	The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1613-20	0.7	79
153	Infectious and malignant complications of TNF inhibitor therapy in IBD. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1835-42, quiz 1843	0.7	79
152	The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. <i>Annals of Internal Medicine</i> , <b>2003</b> , 138, 795-806	8	78
151	A34 TRENDS AND PREDICTORS OF CLOSTRIDIUM DIFFICILE INFECTION AMONG THE CHILDREN OF MANITOBA: A POPULATION-BASED STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 57-58	0.5	78
150	A105 CANADIAN WOMEN WITH IBD ARE MORE LIKELY TO GIVE BIRTH TO LOW BIRTH WEIGHT INFANTS. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 159-160	0.5	78
149	Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1475-82	0.7	75
148	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. <i>Gut</i> , <b>2020</b> , 69, 274-282	19.2	74
147	Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2017</b> , 153, 430-438.e2	13.3	72
146	Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 1005-18	6.1	67
145	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1464-1473	11.5	65
144	The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 942-50	0.7	64
143	The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. <i>Gastroenterology</i> , <b>2004</b> , 127, 403-11	13.3	62
142	What Are Adults With Inflammatory Bowel Disease (IBD) Eating? A Closer Look at the Dietary Habits of a Population-Based Canadian IBD Cohort. <i>Journal of Parenteral and Enteral Nutrition</i> , <b>2016</b> , 40, 405-11	4.2	59
141	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. <i>BMJ The</i> , <b>2016</b> , 352, i581	5.9	59
140	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1412-1422	0.7	57
139	Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 274-83	6.1	54

138	Predictors and risks for death in a population-based study of persons with IBD in Manitoba. <i>Gut</i> , <b>2015</b> , 64, 1403-11	19.2	48
137	Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1647-50	0.7	48
136	Risk factors and management of osteoporosis in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , <b>2014</b> , 30, 168-74	3	47
135	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. <i>Gut</i> , <b>2021</b> , 70, 499-510	19.2	47
134	The role of rapid endoscopy for high-risk patients with acute nonvariceal upper gastrointestinal bleeding. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 21, 425-9		45
133	Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 95-101	0.7	42
132	Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 56-60	1.7	41
131	Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 278-85	6.9	38
130	Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 473-483	4.5	37
129	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , <b>2016</b> , 89, 107-13	4.1	35
128	Characterization of inflammatory bowel disease in elderly patients: A review of epidemiology, current practices and outcomes of current management strategies. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 327-33	2.8	35
127	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1-13	4.5	34
126	The cost-effectiveness of colonic stenting as a bridge to curative surgery in patients with acute left-sided malignant colonic obstruction: a Canadian perspective. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2006</b> , 20, 779-85		34
125	Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 622-30	4.5	33
124	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, S17-S33	0.5	31
123	Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2907-2916	4.5	31
122	Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 519-528	0.7	30
121	Low prevalence of disability among patients with inflammatory bowel diseases a decade after diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1330-7.e2	6.9	30

120	Inflammatory bowel disease and the risk of osteoporosis and fracture. <i>Maturitas</i> , <b>2013</b> , 76, 315-9	5	30
119	The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 1306-15	0.7	30
118	Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. <i>Maturitas</i> , <b>2009</b> , 64, 9-13	5	28
117	Events Within the First Year of Life, but Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , <b>2019</b> , 156, 2190-2197.e10	13.3	27
116	Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1247-55	6.1	27
115	Gastrointestinal symptoms before and during menses in women with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 135-44	6.1	26
114	Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 50-7	6.9	25
113	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, S1-S5	0.5	24
112	Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 409-420	4.5	23
111	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1007-13	6.3	23
110	Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1061-1070.e1	6.9	21
109	Academic Performance among Children with Inflammatory Bowel Disease: A Population-Based Study. <i>Journal of Pediatrics</i> , <b>2015</b> , 166, 1128-33	3.6	21
108	Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. <i>Calcified Tissue International</i> , <b>2012</b> , 91, 356-63	3.9	21
107	Understanding Work Experiences of People with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1688-97	4.5	20
106	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1354-1363	15.5	19
105	Gastrointestinal symptoms before and during menses in healthy women. <i>BMC Womens Health</i> , <b>2014</b> , 14, 14	2.9	19
104	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 1613-1626	5.9	19
103	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 858-865	4.5	18

102	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 766-774	4.5	16
101	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1718-1728	4.5	15
100	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1788-1798.e2	6.9	15
99	The Clinician <sup>®</sup> Guide to Proton Pump Inhibitor Related Adverse Events. <i>Drugs</i> , <b>2019</b> , 79, 715-731	12.1	15
98	Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort: The IBD Self-efficacy Scale. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2165-72	4.5	15
97	Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic hemostasis of high-risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 1685-90	4	15
96	The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, S68-S72	0.5	14
95	The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1277-1290	4.5	14
94	Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1302-1309.e3	6.9	14
93	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn <sup>®</sup> Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, e1-e34	0.5	14
92	Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 88-96	6.1	14
91	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 128-137	0.7	14
90	Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need?. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 532-540	4.5	13
89	Health Care Services in IBD: Factors Associated with Service Utilization and Preferences for Service Options for Routine and Urgent Care. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1461-1469	4.5	13
88	Association between spring season of birth and Crohn <sup>®</sup> disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 277-82	6.9	13
87	The relationship among proton pump inhibitors, bone disease and fracture. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 901-12	4.1	13
86	Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. <i>Canadian Family Physician</i> , <b>2006</b> , 52, 1100-5	0.9	13
85	Assessing the Relationship between Sources of Stress and Symptom Changes among Persons with IBD over Time: A Prospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 1681507	2.8	13

84	Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. <i>Gut</i> , <b>2019</b> , 68, 1597-1605	19.2	13
83	Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 352-359	4.5	12
82	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1615-22	4.5	12
81	Management of acute nonvariceal upper gastrointestinal hemorrhage: comparison of an American and a Canadian medical centre. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2003</b> , 17, 489-95		12
80	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 919-24	4.5	11
79	An assessment of endoscopic and concomitant management of acute variceal bleeding at a tertiary care centre. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 21, 85-90		10
78	The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 743-9	6.1	10
77	Workplace Accommodation for Persons With IBD: What Is Needed and What Is Accessed. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1589-1595.e4	6.9	9
76	Physicians Approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1365-72	6.1	9
75	Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1401-1406	4.5	9
74	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1680-1713	6.9	8
73	Maternal Infections That Would Warrant Antibiotic Use Antepartum or Peripartum Are Not a Risk Factor for the Development of IBD: A Population-Based Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 635-640	4.5	8
72	Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: A population-based study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171266	3.7	8
71	Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 562-570	1.5	7
70	Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1206-1216	0.7	6
69	Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29 Suppl 1, 26-34	2.6	6
68	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	6
67	Colonoscopic screening for colorectal cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2438; author reply 2438-9	27.4	5

66	Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e11317	2	5
65	Ustekinumab for the treatment of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 989-94	4.2	5
64	Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study. <i>Journal of Pediatrics</i> , <b>2019</b> , 206, 20-25	3.6	5
63	Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 190-202	4.5	5
62	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1200-1208.e1	6.9	5
61	Coping with Inflammatory Bowel Disease: Engaging with Information to Inform Health-Related Decision Making in Daily Life. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1247-1256	4.5	4
60	Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1996-2005	4.5	4
59	The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 349	0.7	4
58	Emerging issues in the medical management of Crohn's disease. <i>Current Opinion in Gastroenterology</i> , <b>2016</b> , 32, 103-9	3	4
57	1124 There Is No Decrease in the Mortality From IBD Associated Colorectal Cancers Over 25 Years: A Population Based Analysis. <i>Gastroenterology</i> , <b>2016</b> , 150, S226-S227	13.3	4
56	Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 134-138	4.5	4
55	Concomitant Immunomodulator is Associated with a Decreased Risk of Anti-TNF Discontinuation and Substitution: A Population Based Study. <i>Gastroenterology</i> , <b>2017</b> , 152, S970	13.3	4
54	Utility of the MARS-5 in Assessing Medication Adherence in IBD. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 317-324	4.5	4
53	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 141-154	0.5	4
52	A1 LONGITUDINAL CHANGES IN THE DIRECT COST OF IBD CARE IN THE BIOLOGIC ERA. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, 1-3	0.5	3
51	A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 150-157	4.5	3
50	Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224609	3.7	3
49	Comparing resource utilization and gastrointestinal outcomes in patients treated with either standard-dose or high-dose proton pump inhibitors: a matched cohort study. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 1519-26	4	3



48	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29 Suppl 1, 86-92	2.6	3
47	Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	3
46	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 328-335	4.5	3
45	Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1613-1620	4.5	2
44	IMAGINE Network Randomized Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. <i>BMJ Open</i> , <b>2020</b> , 10, e041733	3	2
43	Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1768-1774	0.7	2
42	Mo1871 - Direct Costs of Care Among Patients with Inflammatory Bowel Disease before and after Initiation of Anti-TNF Therapy. <i>Gastroenterology</i> , <b>2018</b> , 154, S-833	13.3	2
41	What is the role for bisphosphonates in IBD?. <i>Gut</i> , <b>2014</b> , 63, 1369-70	19.2	2
40	Sa1201 Development of an IBD Symptom Self-Report Scale for Research and Clinical Application. <i>Gastroenterology</i> , <b>2014</b> , 146, S-228-S-229	13.3	2
39	223 Patterns of Drug Avoidance in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2013</b> , 144, S-48-S-49	13.3	2
38	Immortal time bias and infliximab-related mortality and malignancy incidence. <i>Gut</i> , <b>2010</b> , 59, 416; author reply 416	19.2	2
37	The Relationship Between Inflammatory Bowel Disease and Bone Mineral Density. Results of a Population-based Study. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, S492	0.7	2
36	Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. <i>Journal of Infection</i> , <b>2020</b> , 81, 758-765	18.9	2
35	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1284-1293	0.7	2
34	Immortal time bias: a likely alternate explanation for the purported benefits of DXA Screening in ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1689	0.7	1
33	Proton pump inhibitors and osteoporosis-related fractures. <i>Cmaj</i> , <b>2009</b> , 180, 643; author reply 643-4	3.5	1
32	The infusion illusion. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3019-21	0.7	1
31	179 Cost-Effectiveness Analysis of Starting a Fecal Microbiota Transplantation (FMT) Unit for the Treatment of Recurrent C. difficile Infection Compared With Antibiotic Therapy. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S110-S110	0.7	1

30	The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. <i>Journal of Clinical Gastroenterology</i> , <b>2019</b> , 53, 553-559	3	1
29	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S40-S45	0.5	1
28	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 131-136	0.5	0
27	Proton pump inhibitors and osteoporosis-related fractures. <i>Cmaj</i> , <b>2009</b> , 180, 643-644	3.5	0
26	The association of efficacy, optimism, uncertainty and health anxiety with inflammatory bowel disease activity.. <i>Journal of Psychosomatic Research</i> , <b>2022</b> , 154, 110719	4.1	0
25	Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 602-608	3	0
24	Time trends and predictors of laboratory-confirmed recurrent and severe infections in Manitoba: a population-based study. <i>CMAJ Open</i> , <b>2020</b> , 8, E737-E746	2.5	0
23	Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 814-832	6.1	0
22	The Cost of Use of the Emergency Department by Persons With Inflammatory Bowel Disease Living in a Canadian Health Region: A Retrospective Population-Based Study. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2020</b> , 3, 135-140	0.5	0
21	Gastroenterologist Consultation Is Uncommon but Associated with Improved Care Among IBD Patients Presenting to Emergency Departments in Winnipeg Hospitals. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 57-64	0.5	0
20	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S61-S67	0.5	0
19	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S1-S9	0.5	0
18	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S27-S33	0.5	0
17	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S46-S53	0.5	0
16	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S54-S60	0.5	0
15	A Preliminary Study of DXA and QCT Derived Femur Cross-Section Stiffness. <i>Applied Mechanics and Materials</i> , <b>2015</b> , 775, 415-419	0.3	
14	Reply. <i>Gastroenterology</i> , <b>2018</b> , 154, 256-257	13.3	
13	The Economics of Inflammatory Bowel Disease. <i>Clinical Gastroenterology</i> , <b>2017</b> , 345-355	0	

12	Reply: To PMID 26077178. <i>Gastroenterology</i> , <b>2015</b> , 149, 1634	13.3
11	The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices. <i>Evidence-Based Medicine</i> , <b>2013</b> , 18, 38-9	
10	Pre-endoscopic PPI therapy reduces recurrent adverse outcomes in acute non-variceal upper gastrointestinal bleeding: authors' Reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 344-345	6.1
9	What Constitutes Frailty In Inflammatory Bowel Disease?. <i>Gastroenterology</i> , <b>2020</b> , 159, 1993	13.3
8	A172 THE ASSOCIATION OF EFFICACY, OPTIMISM, UNCERTAINTY AND HEALTH ANXIETY IN INFLAMMATORY BOWEL DISEASE ACTIVITY OVER TIME. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 183-184	0.5
7	A155 REAL-WORLD USE OF CORTIMENT IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 161-162	0.5
6	Failure to Account for Immortal Person Time Likely Accounts for the Apparent Reduction in Surgery Among Natalizumab Users. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 776	6.9
5	Reply to Letter to Editor of Dr. Elia. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e9	4.5
4	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S10-S19	0.5
3	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S34-S39	0.5
2	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology-The Trends of Disease Over Time. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, S20-S26	0.5
1	A158 COMPARING CORTIMENT AND PREDNISONE IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2022</b> , 5, 33-35	0.5